Misonix Appoints Stavros Vizirgianakis to Board of Directors

         Misonix Appoints Stavros Vizirgianakis to Board of Directors

Board Expands to Seven Members

PR Newswire

FARMINGDALE, N.Y., May 10, 2013

FARMINGDALE, N.Y., May 10, 2013 /PRNewswire/ --Misonix, Inc. (NASDAQ: MSON),
a surgical device company that designs, manufactures and markets innovative
therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo –
facial surgery, neurosurgery,wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, announced today that Mr.
Stavros Vizirgianakis has been appointed to the Misonix Board of Directors.
The addition of Mr. Vizirgianakis expands the Misonix Board to seven members,
with five members considered to be independent directors. Mr. Vizirgianakis is
a Misonix shareholder, having acquired 5.3 percent of the Company's
outstanding common stock in the open market in recent years.

Stavros Vizirgianakis has extensive medical device sales and marketing
experience as a principal in Applied BioSurgical, a large medical device
distributor in South Africa, and as a partner in MD Solutions Australasia PTY
LTD, an Australian-based distributor of medical device products. Both
companies are major distributors for a large number of medical device
companies throughout the world.

Applied BioSurgical and MD Solutions have been exclusive distributors of
Misonix products in their respective territories for many years.

Mr. Michael A. McManus, Jr., president and chief executive officer of Misonix,
said, "We are very pleased to welcome Stavros Vizirgianakis to our Board of
Directors. Stavros has a documented track record of success in marketing
medical devices throughout the world. I have gotten to know Stavros over the
years as he has successfully sold our products internationally. His industry
knowledge, marketing experience, and his vast business relationships will be a
great benefit to Misonix in the coming years."

About Misonix:
Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical
devices. Misonix's therapeutic ultrasonic platform is the basis for several
innovative medical technologies. Addressing a combined market estimated to be
in excess of $3 billion annually; Misonix's proprietary ultrasonic medical
devices are used for wound debridement, cosmetic surgery, neurosurgery,
laparoscopic surgery, and other surgical and medical applications. Additional
information is available on the Company's Web site at www.misonix.com.

Private Securities Litigation Reform Act of 1995
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and
Current Reports on Form 8 K. The Company disclaims any obligation to update
its forward looking relationships.

Misonix Contact:   Investor Relations Contact:
Richard Zaremba    Joe Diaz, Lytham Partners
631 694 9555       602 889 9700
invest@misonix.com mson@lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
Press spacebar to pause and continue. Press esc to stop.